45 results about "Meninges" patented technology

The invention discloses application of a biomarker in diagnosis of lung cancer soft meningeal metastasis. According to the present invention, it is found for the first time that the metabolites such as Indolastic acid, L-Glutic acid, N-Lactoylphenylalanine, cis-Acetic acid, Formiglumic acid and N-Acetylneomic acid in the cerebrospinal fluid have good diagnosis efficiency on the lung cancer soft meningeal metastasis, have high accuracy, high sensitivity and high specificity, can be used as the biological marker of the lung cancer soft meningeal metastasis, and can be used in the effective diagnosis of the lung cancer soft meningeal metastasis. The invention provides a brand-new thought and strategy for research and development of related diagnostic products for the lung cancer soft meningeal metastasis, and has wide application prospects and important transformation significance in the technical field of diagnosis of the lung cancer soft meningeal metastasis.

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

The application discloses a dural membrane scissors for neurosurgery, which is characterized by comprising a scissors provided with a first blade arm and a second blade arm, wherein the first blade arm and the second blade arm are rotationally connected through a first rotating disc and a second rotating disc connected thereto, and a shaft sleeve is arranged at the second rotating disc; through the proper resistance of the air bag, the doctor can exert force with his hand, which can improve the doctor's attention and hand feeling during the operation, and is beneficial to more accurate operation; when the first blade arm and the second blade arm are away from each other, the guide shaft gradually leaves the air bag, but the recovery of the air bag needs a certain reaction time, so that when the first blade arm and the second blade arm are opened outward, the air bag does not generate a counteracting pushing force on the first blade arm and the second blade arm, so that the doctor can slowly open the first blade arm and the second blade arm outward, avoids the interference of the counteracting force of the air bag, and makes the operation more accurate.

The invention discloses an application of GW9662 in treatment of meningeal carcinoma. The application finds that GW9662 can effectively inhibit meningeal carcinoma cells for the first time, the discovery of the application is expected to overcome the existing treatment difficulty, opens up a new path for the treatment of meningeal carcinoma, remarkably improves the treatment effect, prolongs the life of a patient, and has a wide application prospect clinically.

The present invention relates to a spinal needle that clearly identifies the presence of cerebrospinal fluid (CFS) to dispense a drug or anaesthetic in the correct direction and site of the meninges. The response of the sensor to the presence of CFS does not depend on environmental factors and is performed quickly to prevent excessive loss of CFS in the patient. The spinal needle comprises a hub having a proximal end and a distal end, said hub comprising a transparent tank arranged at the proximal end of the hub that is configured to receive CFS, an expandable CFS sensor arranged inside the transparent tank and a connection port arranged at the distal end of the hub configured to couple to a device for medical fluids, and a cannula comprising a tip fluidically connected to the proximal end of the hub.

The application discloses a kind of implanted nerve electrode devices of magnetic control telescopic contact and separation cerebral cortex, belong to brain signal research technical field.It includes: flexible substrate, magnetostrictive deformation substrate, magnetostrictive film, elastic component and electrode;The flexible substrate side is provided with several rectangular grooves arranged in order;Two pieces of the magnetostrictive film are pasted to the two sides of the magnetostrictive deformation substrate, and the magnetostrictive film on one side is used to fix the magnetostrictive deformation substrate in the rectangular groove of the flexible substrate;The electrode is fixed on the magnetostrictive deformation substrate, for collecting electroencephalogram;The elastic component is used to pull the deformed magnetostrictive deformation substrate to restore flat state.The device is fixed under dura mater, and can be bent under the drive of magnetic field, realizes the effective contact of nerve electrode and cerebral cortex, compared with traditional semi-invasive nerve electrode, improves the detection quality and stability of electroencephalogram.

The application discloses a marker for depression and application thereof in prevention and treatment of depression. Through the marker, whether an individual is suffering from depression can be detected and diagnosed, so that corresponding treatment strategies can be given in time, and hidden troubles brought by depression to the individual can be reduced. The application also discloses application of the marker in prevention and treatment of depression phenotype. Taking a marker with specific up-regulation as an example, through blocking the function of the marker, prevention and treatment of depression can be realized. Specifically, in addition to specific material markers, it is disclosed that abnormality of meningeal lymphatic vessels is closely related to depression phenotype, and detection of the meningeal lymphatic vessels is expected to be a new marker for early diagnosis and prediction of clinical depression treatment effectiveness. Improvement of the meningeal lymphatic vessels is expected to be applied to treatment of depression and other neurosychiatric diseases related to stress and play an effective treatment role.

The invention belongs to the technical field of medicine, discloses a skull rapid growth marker and application thereof, and provides a skull rapid growth marker based on a pressure / dura mater FAK-Twist1 pathway and an application method of the marker in child skull defect repair. By detecting the expression level of the marker, the growth and development state of the pediatric skull can be accurately judged, and a scientific basis is provided for clinical doctors to select proper skull repair opportunities, so that the success rate and safety of pediatric skull defect repair operations are improved, and postoperative complications are reduced. The rapid skull growth markers determined by the invention are closely related to the growth and development mechanism of the child skull based on a pressure / dura mater FAK-Twist1 pathway, and the growth state of the skull can be accurately reflected by detecting the expression level of the markers, so that a reliable diagnostic basis is provided for opportunity selection of a child skull defect repair operation.

The invention belongs to the field of biological medicines, and particularly relates to a medicine for treating meningeal metastasis of malignant tumors with NTRK and / or ROS1 mutations and a preparation method, and the medicine is a freeze-dried powder preparation or injection for subarachnoid space injection of NTRK / ROS1-TKIs. The invention also provides an application of the NTRK / ROS1-TKIs in preparation of a medicine for treating meningeal metastasis of malignant tumors with NTRK and / or ROS1 mutation. The prepared NTRK / ROS1-TKIs injection can be directly injected into the subarachnoid space of a patient, the drug concentration in cerebrospinal fluid of the patient is greatly improved, the cerebrospinal fluid / plasma concentration ratio can reach 20 times or more, the problem of insufficient dosage caused by the blood-brain barrier after the targeted drug is orally taken can be completely solved, and the drug has the advantages of fast effect taking, no toxic or side effect and no toxic or side effect. The treatment effect on meningeal metastasis of malignant tumors such as lung cancer can be obviously improved.

The invention relates to the technical field of image processing, in particular to a brain tumor focus area segmentation method based on CT image analysis. The method comprises the following steps: segmenting a meninx CT image to obtain an initial segmentation region, and preprocessing the initial segmentation region to obtain an enhanced image; obtaining a gray gradient direction vector of each pixel point in the enhanced image; skeleton lines in each foreground area and tangent lines of all end points of all the skeleton lines are obtained, and then suspected cut-off end points of all the end points are obtained; according to the gray gradient direction vector of each pixel point of the foreground area where each suspected truncation end point of one end point is located, screening the pixel points of the area where each suspected truncation end point is located to obtain disordered pixel points of the end point, and further obtaining each tumor part area of the end point; and taking the central point of each tumor partial region of each end point as a seed point of region growth, and respectively carrying out region growth in each tumor partial region to obtain a tumor region. According to the invention, the brain tumor region can be effectively segmented.

The invention discloses a kit for rapidly and efficiently diagnosing lung cancer meningeal metastasis, and relates to the technical field of medical equipment, and the key points of the technical scheme are as follows: the kit is a disposable plastic shell, and four independent chromatography channels are arranged in parallel in the kit, namely a Compleent C7 channel, a Frizzled-9 channel, an Interleukin-1 receptor protein channel and an Alpha-1-anticmotrypsin channel. Four markers can be detected at the same time, when the kit is used for diagnosing lung cancer meningeal metastasis, the dosage of cerebrospinal fluid can be reduced, the diagnosis sensitivity is improved, the detection time is shortened, the sampling frequency is reduced, and by setting an objective interpretation threshold value and an automatic analysis module, subjective judgment errors are reduced, and diagnosis consistency and repeatability are improved.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The utility model discloses a scalp scar incision knife for the edge of a bone window, which is divided into an L type and a T type, and each type is divided into two edging directions, namely a clockwise edging direction and an anticlockwise edging direction; the T-shaped scalpel comprises a scalpel handle, a first blade or a second blade, the scalp of a surgical part of a patient is transversely and longitudinally cut open at the same time through the additional arrangement of the first blade or the second blade, and the convenience of medical staff in surgical use is improved; a downward edged blade and an upward edged blade are arranged on the blade side, the skull side blade is edged downwards, periosteum and skull of a patient are separated, the downward blade can prevent the scalp from being too thin, and it is guaranteed that the blade is tightly attached to the surface of the skull to be pushed. The blade in the bone window is edged upwards, so that damage to meninx and brain tissue of a patient caused by the blade can be avoided, the use safety is improved, the situation that medical staff frequently replace tools in the operation process is avoided, and the use difficulty of the medical staff is reduced.

The invention belongs to the field of biological medicine, and particularly relates to a medicine for treating EGFR mutation non-small cell lung cancer meningeal metastasis, application, a medicine box and a preparation method of the medicine, the medicine is a freeze-dried powder preparation or injection of EGFR-TKIs for subarachnoid space injection, the amount of EGFR-TKIs per person in the medicine is 0.01-5 mg, and the amount of EGFR-TKIs in the medicine is 0.01-5 mg. The injection method comprises any one of lumbar puncture, bridge forebay indwelling catheter injection and Ommaya capsule injection. The prepared EGFR-TKIs injection can be directly injected into the subarachnoid space, the drug concentration in cerebrospinal fluid of a patient is greatly improved, the cerebrospinal fluid / plasma concentration ratio of the EGFR-TKIs injection is increased from far less than 1 to more than 2 times and even can reach more than 10 times, and the EGFR-TKIs injection can completely solve the problem of insufficient dosage caused by a blood-brain barrier after oral administration of a targeted drug and has a good application prospect. The medicine takes effect quickly, and the treatment effect on lung cancer meningeal metastasis can be remarkably improved.

The invention relates to a sprayable medical hydrogel and application thereof, the injectable medical hydrogel comprises a first component and a second component, the first component comprises chitosan or chitosan oligosaccharide with high deacetylation degree or a derivative thereof, and the second component comprises chitosan with high deacetylation degree or chitosan oligosaccharide with high deacetylation degree or chitosan oligosaccharide with high deacetylation degree or chitosan oligosaccharide with high deacetylation degree or chitosan oligosaccharide with high deacetylation degree; the second component is one of aldehyde group terminated multi-arm polyethylene glycol or succinimide terminated multi-arm polyethylene glycol; the medical hydrogel is absorbable medical hydrogel formed by in-situ crosslinking after a first component and a second component are subjected to bi-component injection physical mixing. The medical hydrogel can be used for sealing wounds of injured parts of dura mater or spinal cord; the temperature-sensitive hydrogel overcomes the defects of slow curing time and low gel strength of temperature-sensitive hydrogel, can be polymerized without open ultraviolet irradiation, and is suitable for in-vivo injection.

The invention discloses a method for constructing a model for accurately predicting meningeal metastasis risk of non-small cell lung cancer based on plasma protein and application, and relates to the technical field of biological medicine. Aiming at the problems of late discovery and difficult diagnosis of NSCLC-LM, the inventor tries to adopt an Olink proteomics technology for the first time to know whether an LM risk exists or not in advance by detecting specific plasma protein of a patient in a relatively non-invasive manner, so that the patient is helped to find and treat early. Therefore, the inventor firstly collects blood samples of LM and nLM patients, then constructs a risk prediction model by using a training set, and finally judges the efficiency of the model through a verification set. A result shows that five specific proteins, namely FGF2, CD4, IL15, CXCL12 and PDCD1LG2, participate in model construction, the area under a queue curve is 0.8 or above, and the sensitivity and the specificity both reach relatively high levels. The invention has great significance in the fields of early diagnosis and screening of NSCLC-LM and the like.

This invention discloses a submillimeter-level diffusion magnetic resonance imaging (DTI) method for extracting the radial index of cortical layered cognitive structures, relating to the field of medical image processing technology. This invention aims to address the problems of existing technologies failing to accurately quantify the directionality of cortical microstructures and neglecting the heterogeneity of cortical layering. The method includes: acquiring DTI data and performing high-fidelity preprocessing such as MP-PCA denoising, Gibbs artifact removal, and Gaussian process distortion correction; estimating the diffusion tensor and extracting the principal feature vector based on the preprocessed data; reconstructing the cortical white matter and pia mater surface using T1 images and extracting the normal vector; calculating the absolute value of the dot product of the diffusion principal feature vector and the surface normal vector to construct a radial index map; and segmenting the cortex into multiple intermediate layers based on the principle of equal volume and extracting layering parameters. Through refined high-resolution data processing and geometric modeling, this invention can accurately quantify the radial alignment integrity of cortical nerve fibers, providing highly sensitive imaging markers for cognitive disorders such as schizophrenia.

A dura mater incision device for neurosurgery, wherein a rotating column (2) is provided on a movable cabinet mechanism by means of a rotary damper (1); the upper end of the rotating column (2) is provided with a connecting rocker arm (4) by means of a mounting base (3); an end portion of the connecting rocker arm (4) is provided with a connecting mechanism; the front end of a handpiece (5) is provided with a guard plate (7) by means of a hinged connecting base (6); a movable carriage (9) is provided above the guard plate (7) by means of a movable guide groove (8); the lower side of the movable carriage (9) is provided with a dural knife (10) by means of an adjusting base mechanism; and a driving mechanism is provided between the handpiece (5) and the movable carriage (9). By rotatably arranging the connecting rocker arm (4), movable support can be provided for an incision knife mechanism. This design requires only manual gripping for directional adjustment and movement, without the need to fully hand-hold the incision knife mechanism during operation, thereby relieving the surgeon from the gravitational load of the incision knife mechanism, increasing the precision of surgical manipulation. The dural knife is driven by the driving mechanism to move back and forth to simulate the action of manual cutting, and the cutting depth of the dural knife can also be controlled, thereby further increasing the precision of dural incision, allowing for more effortless and convenient cutting.

Surgical constructs, assemblies, kits and methods of tissue fixation are disclosed. A suture passing instrument includes a curved tip integral with a distal end of a shaft, a hand assembly mounted on a proximal end of the shaft, and a flexible strand attached to one or two needles and loaded through a cannulation of the shaft. The curve-shaped tip is adapted to engage dural tissue during repairs of the dura mater. The suture passing instrument can grasp and manipulate dura mater and can allow multiple suture passes through the dura mater without removal of the instrument from the durotomy site. The suture passing instrument is provided with a safety mechanism that prohibits the needle(s) to be fired into nerves, providing a safe, reliable, inexpensive, and speedy repair of a durotomy.

This invention provides a novel target PDE4B for the prevention and treatment of Cryptococcus neoformans brain infection. Specifically, it relates to the application of drugs targeting phosphodiesterase PDE4B in the preparation of drugs for the prevention and / or treatment of Cryptococcus neoformans meningoencephalitis. The drug targeting PDE4B is the PDE4B agonist MR-L2 (CAS: 2374703-19-0). The PDE4B agonist MR-L2 described in this invention can significantly reduce Cryptococcus neoformans brain infection, providing an effective prevention and treatment method for Cryptococcus neoformans meningoencephalitis.

This invention relates to the field of biomedicine, and particularly to the application of anti-VLA4 therapy in antidepressant treatment by inhibiting the migration of γδ T cells to the central nervous system. This invention utilizes anti-VLA4 antibody treatment to reduce the infiltration of γδ T cells into the meninges and brain parenchyma of mice, revealing that anti-VLA4 inhibition of peripheral T cell migration can block CUMS-induced depressive-like behaviors, providing a novel strategy for the treatment of depression.

Systems and methods for implanting an endovascular shunt in a patient is disclosed. The system having an expandable anchor configured for being deployed in a dural venous sinus of a patient at a location distal to a curved portion of a wall of an inferior petrosal sinus (IPS) of the patient; an elongate guide member coupled to, and extending proximally from, the anchor; a shunt delivery catheter having a first lumen configured to receive the guide member, and a second lumen extending between respective proximal and distal openings in the shunt delivery catheter, the shunt delivery catheter further having a penetrating element coupled to a distal end of the catheter; and the system further having a guard at least partially disposed over, and movable relative to, the penetrating element.

The utility model relates to medical instrument technical field discloses a kind of clamping position shunt and interventional medical instrument.The utility model includes a kind of clamping position shunt, is conveyed and is disposed in the ventricular system and venous system of patient by conveying system and exports cerebrospinal fluid in the ventricular system of patient to venous system, the dura mater between ventricular system and venous system is equipped with puncture hole, the puncture catheter with puncture needle head is included in conveying process, clamping position shunt is arranged in puncture catheter, the proximal end side wall of puncture needle head is equipped with at least one shunt tube installation slot, clamping position shunt includes the shunt tube body for being disposed in venous system and the distal end part for being disposed in ventricular system.The utility model is improved by clamping position shunt and its conveying system, not only simplifies conveying system structure, so that the operation of conveying system is more convenient, operation risk is lower, and shunt tube can also be provided with protection to puncture catheter.

The application discloses a method for constructing a precise prediction non-small cell lung cancer meningeal metastasis risk model based on plasma proteins and application, and relates to the technical field of biological medicine. In view of the problems of NSCLC-LM late discovery and difficult diagnosis, the inventors first attempt to use Olink proteomics technology to detect specific plasma proteins of patients in a relatively non-invasive way to know whether there is a LM risk in advance, and help patients to discover and treat early. For this purpose, the inventors first collect blood samples of LM and nLM patients, then use the training set to construct a risk prediction model, and finally judge the model performance through the validation set. The results show that FGF2, CD4, IL15, CXCL12 and PDCD1LG2 5 specific proteins are involved in model construction, and the area under the curve of the cohort is above 0.8, and the sensitivity and specificity also reach a high level. The application has great significance in the field of early diagnosis and screening of NSCLC-LM.

The invention relates to the technical field of cranial-brain interface modeling, and discloses a cranial-brain interface modeling method based on a thick-shell element, comprising: loading a head finite element model to clean cranial-brain interface nodes, generating a thick-shell element to simulate a boundary cell layer between a dura mater and an arachnoid, and optimizing mesh quality; the thick shell unit is endowed with orthotropic material properties; setting the maximum principal stress as a failure criterion; the failure threshold is optimized through simulation-comparison-optimization circulation and machine learning by using classical corpse test data; iteratively determining an optimal failure threshold value and verifying the reliability; the technical problem that existing cranial-brain interface modeling cannot meet accurate and efficient requirements is solved.

The application belongs to the field of biological medicine, and particularly relates to a drug for treating EGFR mutant non-small cell lung cancer meningeal metastasis, application, a medicine box and a preparation method of the drug, the drug is a lyophilized powder preparation or injection solution for subarachnoid injection of EGFR-TKIs, the amount of EGFR-TKIs in the drug is 0.01-5 mg per person, and the injection method comprises any one of lumbar puncture, injection through a catheter indwelled in the pre-bridge pool and Ommaya capsule injection. The prepared EGFR-TKIs injection solution can be directly injected into the subarachnoid space, greatly improving the drug concentration in the cerebrospinal fluid of the patient, the cerebrospinal fluid / plasma concentration ratio is increased from far less than 1 to more than 2 times, and even more than 10 times. The application can completely solve the problem of insufficient dose caused by the blood-brain barrier after oral administration of a targeted drug, and the drug has fast effect and can significantly improve the treatment effect of lung cancer meningeal metastasis.

Systems and methods for implanting an endovascular shunt in a patient is disclosed. The system having an expandable anchor configured for being deployed in a dural venous sinus of a patient at a location distal to a curved portion of a wall of an inferior petrosal sinus (IPS) of the patient; an elongate guide member coupled to, and extending proximally from, the anchor; a shunt delivery catheter having a first lumen configured to receive the guide member, and a second lumen extending between respective proximal and distal openings in the shunt delivery catheter, the shunt delivery catheter further having a penetrating element coupled to a distal end of the catheter; and the system further having a guard at least partially disposed over, and movable relative to, the penetrating element.

A pharmaceutical composition, comprising panobinostat and tazemetostat. Combination of tazemetostat which is an EZH2 inhibitor with panobinostat, pembrolizumab and ipilimumab is clinically used for treating patients suffering from later-stage diffuse midline glioma, H3K27-altered, accompanied with leptomeningeal / pia mater spinalis spread, and patients suffering from primary, relapsing and progressing diffuse midline glioma, H3K27-altered. The pharmaceutical composition has remarkable curative effects, can obviously inhibit tumor growth, reduce the tumor volume, improve the life quality for patients, and prolong the survival time of patients.

The application relates to the field of interventional medical technology, in particular to a percutaneous interventional venous sinus puncture access device. The access device is formed by the mutual cooperation of a balloon catheter, a deflecting catheter and a puncture guide wire, can puncture into the subarachnoid cavity in the cranial cavity on the venous sinus without damaging the brain, break the dura mater and arachnoid, construct a stoma between the pontocerebellar angle pool and the inferior petrosal sinus, and make the cerebrospinal fluid flow from the subarachnoid cavity to the venous sinus, to the jugular vein and to the heart, and participate in blood circulation. The access device can also be used for delivering a shunt, so that the hydrocephalus which can only be effectively treated by operation in the past can be treated by a minimally invasive interventional method, the access device is not used for surgical open operation, the intraoperative trauma is reduced, the operation time is saved, and the possibility of postoperative infection is greatly reduced.

An RNAi agent and composition that inhibits expression of transthyretin (TTR) for use in the treatment and / or prevention of ATTR-associated diseases, including ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis disease, leptomeningeal / central nervous system amyloidosis disease.